Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Immunotherapy for Relapsed Pediatric B-ALL
NCT01700946Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2013
- Primary completion
- Jul 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of Natural killer cell infusion in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoblastic lymphoma (LL) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: 3-year Overall Survival Rate and 3-year Event-free Survival Rate. Started Apr 2013; status: completed.
02
Drugs
Natural killer cell infusion
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT01700946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700946.